Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees

Vandana Singh
1 min read
0
In this article:

  • Instil Bio Inc (NASDAQ: TIL) announced a reprioritization of its clinical programs to focus on developing its CoStAR-TIL product candidates.

  • The company has prioritized the development of its proprietary, genetically-engineered CoStAR-TIL programs, designed to boost the efficacy of T cells within the tumor microenvironment (TME).

  • Instil's lead CoStAR-TIL program, ITIL-306 is in a Phase 1 dose escalation trial in non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma.

  • The company expects to report data from the dose escalation cohorts of Phase 1 ITIL-306 study in 2023.

  • In October, the company voluntarily paused enrollment in its ongoing ITIL-306 trial as part of its overall manufacturing analysis.

  • Instil is undertaking a reduction in its U.S. workforce of approximately 60% to realign its operating model from a registration-focused company to a development-stage company.

  • Instil is discontinuing its ITIL-168 clinical programs, the DELTA-1 trial in advanced melanoma and the DELTA-2 trial in NSCLC, cervical cancer, and head and neck squamous cell carcinoma.

  • Price Action: TIL shares are down 17.20% at $1.01 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories